- Open
- 1.10
- High
- 1.15
- Low
- 1.05
- Close
- 1.08
- Change
- -0.05 (-4.55%)
- Volume
- 4,452,556
⌘K
| 6 May 2026 | 11:56:49 | Holding(s) in Company |
| 5 May 2026 | 07:00:13 | Sussex NHS Trust transitions MT-RNR1 test to BAU |
| 21 Apr 2026 | 07:00:07 | NHS England commercial strategy for MT-RNR1 |
| 20 Apr 2026 | 07:00:08 | Interactive Investor Hub Updates |
| 16 Apr 2026 | 07:00:07 | CYP2C19 kit implemented in North Bristol NHS Trust |
| 22 Dec 2025 | Annual Report and Accounts (to 2025-06-30) | |
| 23 Dec 2024 | Annual Report and Accounts (to 2024-06-30) | |
| 2 Jan 2024 | Annual Report and Accounts (to 2023-06-30) |
genedrive plc is a company that specializes in molecular diagnostics. They are focused on creating a point-of-need platform that is affordable, fast, flexible, user-friendly, and reliable. This platform is designed to diagnose infectious diseases, as well as to help with patient stratification, pathogen detection, and other medical needs.
| 6 May 2026 | 11:56:49 | Holding(s) in Company |
| 5 May 2026 | 07:00:13 | Sussex NHS Trust transitions MT-RNR1 test to BAU |
| 21 Apr 2026 | 07:00:07 | NHS England commercial strategy for MT-RNR1 |
| 20 Apr 2026 | 07:00:08 | Interactive Investor Hub Updates |
| 16 Apr 2026 | 07:00:07 | CYP2C19 kit implemented in North Bristol NHS Trust |
| 22 Dec 2025 | Annual Report and Accounts (to 2025-06-30) | |
| 23 Dec 2024 | Annual Report and Accounts (to 2024-06-30) | |
| 2 Jan 2024 | Annual Report and Accounts (to 2023-06-30) |
genedrive plc is a company that specializes in molecular diagnostics. They are focused on creating a point-of-need platform that is affordable, fast, flexible, user-friendly, and reliable. This platform is designed to diagnose infectious diseases, as well as to help with patient stratification, pathogen detection, and other medical needs.
| 28 Oct 2019 |
| Acceleration of news flow expected |
| 18 Jul 2019 | Hepatitis C market frustrations |
| 8 Apr 2019 | First commercial sales in new focus area: bio-threats |
| 10 Dec 2018 | Accelerating into fiscal 2019 with first sales |
| 28 Oct 2019 |
| Acceleration of news flow expected |
| 18 Jul 2019 | Hepatitis C market frustrations |
| 8 Apr 2019 | First commercial sales in new focus area: bio-threats |
| 10 Dec 2018 | Accelerating into fiscal 2019 with first sales |